27 April 2022 | News
Enter second phase of strategic partnership for co-creation of innovative new medicines and medical solutions
image credit- shutterstock
The University of Tokyo and Astellas Pharma Inc., in Japan, have entered the second phase of their collaboration for co-creating innovative new medicines and medical solutions, called the Astellas Alliance Acceleration Programme (AAAP).
In its first phase, from September 2020 to March 2022, AAAP established a base for its collaborative relationship at the university’s Institute for Life Science Research and Education, and the University of Tokyo Center of Innovation. During this period, medical and pharmaceutical researchers from the two university organizations and drug discovery researchers from Astellas nurtured an environment for open-minded discussions, and as a result, several new research projects were identified and launched successfully.
In the second phase, the University of Tokyo will expand its partnership involvement to include all of its institutions. Furthermore, a newly appointed AAAP-dedicated project manager will be stationed at the university to faciliate the collaboration. These additional intiatives will allow the strategic partners to build new research projects, by combining the University of Tokyo’s cutting-edge scientific research with Astellas’ drug discovery know-how.